Healthcare Industry News: Bard
News Release - March 17, 2010
Caron D'Ambruso Joins SafeStitch as Vice President of Sales and MarketingSafeStitch to Unveil AMID Stapler™ at American Hernia Society Annual Meeting on March 17, 2010
MIAMI--(HSMN NewsFeed)--SafeStitch Medical, Inc. (OTCBB: SFES ) announced that Caron D’Ambruso has joined SafeStitch as its Vice President of Sales and Marketing. Caron will play a critical role in leading the Company’s commercialization of recently approved products beginning with leading the unveiling of the AMID Stapler™ at the American Hernia Society annual meeting in Orlando, Florida on March 17, 2010.
Ms. D’Ambruso’s previous experience includes Global Vice President of Sales and Marketing at Kensey Nash Corporation, Group Director of Endovascular Marketing at Johnson and Johnson’s Cordis, Vice President of Sales and Marketing at Scion Cardiovascular, Portfolio Leader at Cordis Corporation and Product Manager at CR Bard. During her tenure at Cordis, Ms. D’Ambruso won the President’s Award for Team Leadership for her team work on the stent delivery system.
“We are pleased to welcome Caron to the team. She has extensive sales and marketing experience, including previously increasing sales and market share of Cordis’ balloon catheters and guiding catheters to market leading positions prior to Cordis Corporation's acquisition by Johnson and Johnson. Caron will lead our effort to introduce the AMID Stapler™ which is the first surgical stapler designed specifically for use in inguinal hernia repairs using the Lichtenstein method, in which mesh is implanted for reinforcement. We believe the AMID Stapler™ will make the procedure easy, fast, safe, and potentially reduce post-operative pain.” said Jeffrey G. Spragens, President and CEO of SafeStitch.
Ms. D’Ambruso received an RN from the Newton Wellesley School of Nursing and a BA in Economics from Harvard University.
About SafeStitch Medical, Inc.
Miami-based SafeStitch Medical, Inc. is a medical device company primarily developing endoscopic and minimally invasive surgical devices. SafeStitch's product portfolio includes endoscopic gastroplasty devices for bariatric (obesity) surgery and repair of gastroesophageal reflux disorder (GERD), as well as the AMID Stapler™, Standard BiteBlock, Airway BiteBlock and SMART DilatorTM. SafeStitch has also started development of devices for excision and diagnosis of Barrett's esophagus and natural orifice transluminal endoscopic surgery (NOTES). Information about the Company may be found on its website at: www.safestitch.com.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development, commercialization and marketing efforts, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors, including those described in our filings with the Securities and Exchange Commission, could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include SafeStitch’s ability to market and launch its products, including the AMID Stapler™, our ability to integrate new personnel into our existing management team, that the design of the AMID Stapler™ may not have the versatility to perform as anticipated or make the hernia repair procedure easier, faster or safer, or potentially reduce post-operative pain, that the commercialization and launch of the AMID Stapler™ and our other devices may be delayed or may be unsuccessful, that we will be unable to successfully develop and commercialize our minimally invasive gastroplasty devices for obesity and GERD procedures, that our devices under development may not achieve the expected results or effectiveness and may not generate data that would support their approval or marketing, that others may develop products and devices, including other devices for hernia repair, obesity or GERD procedures, which are superior to our devices, and that our devices may not have advantages over presently marketed products or devices or products or devices under development by others. In addition, forward-looking statements may also be adversely affected by risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Source: SafeStitch Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.